Scandinavian ChemoTech's COO completes his assignment
Scandinavian ChemoTech's COO Urban Widen ends his interim assignment after a job well done.
On a consulting basis, Urban Widén has been linked to Scandinavian ChemoTech as COO to help build a new expansive strategy. This assignment has now come to a successful end.
“Urban has, with his long experience from the industry, been an important asset in the Company's work towards a new strategy and his insights has been essential for the Company's new path choice. I want to thank Urban for a strong effort and wish him luck in his continued career. "- says Mohan Frick, CEO and co-founder of ChemoTech
This disclosure contains information that ChemoTech is obliged to make public pursuant to the EU Market Abuse Regulation (EU nr 596/2014). The information was submitted for publication, through the agency of the contact person, on 22-10-2021 18:30 CET.
For more information, please contact:
Mohan Frick, CEO
Phone: +46 (0)10-218 93 00
Certified Adviser: Erik Penser Bank, Tel: +46 8 463 80 00, E-mail: certifiedadviser@penser.se
Scandinavian ChemoTech AB (publ)
ChemoTech is a Swedish medical technology company based in Lund that has developed a patented technology platform to offer cancer patients access to a new treatment alternative, Tumour Specific Electroporation™ (TSE), available for treatment of both humans and animals. There are a large number of cancer patients whose tumours for various reasons cannot be treated by conventional methods but where TSE can be a solution. Therefore, the company continuously evaluates new opportunities and areas of application for the technology. ChemoTech's shares (CMOTEC B) are listed on Nasdaq First North Growth Market in Stockholm and Erik Penser Bank is the company's Certified Adviser. Read more at: www.chemotech.se.